Bempedoic Acid (Nexletol): How It Compares to Statins for LDL Lowering

What Is Bempedoic Acid and How Does It Work?

Bempedoic acid blocks ATP-citrate lyase (ACL), an enzyme that sits one step upstream of HMG-CoA reductase, the target of all statins. By reducing hepatic cholesterol synthesis at this earlier step, it up-regulates LDL receptors and clears LDL-C from the bloodstream. The critical pharmacological difference from statins: ACL is expressed in the liver but not in skeletal muscle, which is why bempedoic acid does not deplete muscle coenzyme Q10 the way statins can.

The drug is a prodrug. Liver-specific very-long-chain acyl-CoA synthetase-1 (ACSVL1) converts it to its active form only after first-pass hepatic metabolism. That tissue selectivity is the reason myopathy rates in clinical trials did not exceed placebo [1].

The FDA granted approval in February 2020 under NDA 211616, based primarily on a package of four Phase 3 trials and the then-pending CLEAR Outcomes cardiovascular outcomes trial [2]. A fixed-dose combination tablet pairing bempedoic acid 180 mg with ezetimibe 10 mg (brand name Nexlizet, formerly Liptruzet was a different combination) received approval the same month.

Bempedoic acid fits patients who cannot tolerate statins, who need modest additional LDL lowering on top of maximum-tolerated statin therapy, or who refuse injectable PCSK9 inhibitors like evolocumab (Repatha) or alirocumab (Praluent).

CLEAR Outcomes: The Cardiovascular Evidence Base

CLEAR Outcomes is the definitive trial for bempedoic acid. Sponsored by Esperion Therapeutics and published in the New England Journal of Medicine in March 2023, the trial enrolled 13,970 statin-intolerant patients with or at high risk for cardiovascular disease and randomized them to bempedoic acid 180 mg daily or placebo [3].

At a median follow-up of 40.6 months, the primary 4-component MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke, or coronary revascularization) occurred in 11.7% of bempedoic acid patients versus 13.3% placebo (HR 0.87; 95% CI 0.79-0.96; P<0.001) [3]. That is a 13% relative risk reduction.

LDL-C fell by a mean of 21.1 mg/dL (approximately 21.4% from baseline) at six months in the bempedoic acid group [3]. The trial excluded patients currently tolerating any statin, so it does not tell us what bempedoic acid adds on top of high-intensity statin therapy in statin-tolerant individuals.

Three secondary MACE components showed directionally consistent results: fatal or nonfatal MI was reduced by 23% (HR 0.77; 95% CI 0.66-0.91) and fatal or nonfatal stroke trended lower without reaching statistical significance at 0.7 fewer events per 100 patient-years [3].

The CLEAR Harmonize trial (N=2,230), one of the Phase 3 registration studies, showed LDL-C reductions of 18.1% versus placebo at 12 weeks when added to maximally tolerated statin therapy [4]. That number is more modest than CLEAR Outcomes because baseline LDL-C was already partially controlled by background statin use.

Bempedoic Acid vs. Atorvastatin (Lipitor)

Atorvastatin is the most prescribed lipid-lowering drug in the United States and the global benchmark for LDL lowering. High-intensity dosing (40-80 mg/day) reduces LDL-C by 43-50% from baseline, according to the ACC/AHA 2018 Cholesterol Guideline [5]. Moderate-intensity atorvastatin 10-20 mg lowers LDL-C by 30-40%.

Bempedoic acid at 180 mg produces roughly half the LDL-C reduction of high-intensity atorvastatin. That gap matters when a patient has ASCVD and needs to reach an LDL-C target below 70 mg/dL, or below 55 mg/dL per the more aggressive 2019 ESC/EAS guidelines. For those patients, bempedoic acid alone is rarely sufficient.

Where bempedoic acid leads: muscle safety. The CLEAR Outcomes trial found no statistically significant difference in creatine kinase (CK) elevations between bempedoic acid and placebo [3]. Atorvastatin-induced myopathy, while rare (approximately 1 per 10,000 patient-years for frank rhabdomyolysis), is the leading reason patients discontinue statin therapy. An estimated 5-10% of statin users report muscle symptoms severe enough to cause non-adherence, though nocebo effects confound that number substantially [6].

Cost is another practical difference. Generic atorvastatin 40 mg costs under $15 per month at most pharmacy chains. Nexletol carries a list price near $400/month with no generic available as of early 2025.

Clinical positioning: bempedoic acid is not a substitute for atorvastatin in patients who can tolerate statins. It is an appropriate substitute for patients in whom atorvastatin and at least one other statin have been tried and discontinued due to myalgia or elevated liver enzymes.

Bempedoic Acid vs. Rosuvastatin (Crestor)

Rosuvastatin is the most potent statin on a milligram-per-milligram basis. At 40 mg/day (the maximum approved dose in the United States), rosuvastatin lowers LDL-C by 55-63%, a larger reduction than atorvastatin at equivalent intensities [5]. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced first major cardiovascular event by 44% versus placebo in patients with elevated hsCRP but LDL-C below 130 mg/dL [7].

Bempedoic acid does not approach that LDL-lowering ceiling. The drug's 21-24% monotherapy reduction positions it closer to moderate-intensity statin territory. Combined with ezetimibe 10 mg as Nexlizet, the reduction climbs to 36-38%, approaching but not matching high-intensity rosuvastatin [8].

Rosuvastatin is also less susceptible to drug interactions via CYP3A4 compared to atorvastatin, since it is metabolized mainly by CYP2C9. Bempedoic acid does not use CYP pathways significantly, but it does inhibit organic anion-transporting polypeptides (OATP1B1/1B3). That interaction raises systemic exposure of co-administered statins, particularly simvastatin and pravastatin, necessitating dose caps when used in combination (simvastatin max 20 mg; pravastatin max 40 mg per Nexletol prescribing information) [2].

Bempedoic Acid vs. Simvastatin (Zocor)

Simvastatin was the dominant LDL-lowering drug of the 1990s and early 2000s. The 4S trial (N=4,444) was among the first to show mortality benefit from lipid lowering, with simvastatin reducing total mortality by 30% over a median 5.4 years in post-MI patients with LDL-C 188-310 mg/dL [9].

Simvastatin has since fallen in prescribing frequency because of two limitations. First, the FDA placed a 2011 restriction on simvastatin 80 mg due to a 1-in-52 risk of myopathy at that dose seen in the SEARCH trial [10]. Second, the drug interacts with a long list of CYP3A4 inhibitors, including several antibiotics, antifungals, and calcium channel blockers, limiting its usability in polypharmacy patients.

Bempedoic acid is free of CYP3A4-related interactions, which makes it a better-fit alternative for patients on complex medication regimens. The OATP interaction caveat described above still applies: if bempedoic acid is added to a patient already on simvastatin, the simvastatin dose must be capped at 20 mg/day to avoid myopathy risk from elevated simvastatin plasma concentrations [2].

For patients whose primary barrier to statin use is muscle pain on simvastatin, switching to a different statin before prescribing bempedoic acid remains the preferred ACC/AHA strategy, since muscle symptoms do not always recur on an alternative statin [5].

Bempedoic Acid vs. Ezetimibe (Zetia) and Combination Therapy

Ezetimibe works by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. As monotherapy it lowers LDL-C by approximately 18-20%, comparable to bempedoic acid monotherapy [11]. The IMPROVE-IT trial (N=18,144) showed that ezetimibe added to simvastatin reduced the composite cardiovascular endpoint by an absolute 2% over 7 years (32.7% vs. 34.7%; HR 0.936; P=0.016) versus simvastatin alone, confirming LDL lowering below 70 mg/dL with non-statin agents translates to clinical benefit [11].

The most relevant combination data for bempedoic acid comes from the Phase 3 trial of the fixed-dose Nexlizet tablet. In the CLEAR Tranquility study and complementary registration work, bempedoic acid 180 mg plus ezetimibe 10 mg reduced LDL-C by 36.2% from baseline compared to placebo after 12 weeks (P<0.001) [8]. That combination gives statin-intolerant patients a genuinely meaningful LDL reduction without muscle risk from either agent.

The HealthRX clinical team uses the following decision framework for statin-intolerant patients needing LDL-C reduction below 100 mg/dL:

1. Confirm true intolerance. Re-challenge with a low-dose alternative statin (rosuvastatin 5-10 mg every other day) before labeling a patient "statin-intolerant." The SAMSON trial (N=60, crossover design) found that 90% of statin-attributed muscle symptoms were nocebo-related [6].
2. If statin intolerance confirmed: Add ezetimibe 10 mg first (lowest cost, established MACE benefit from IMPROVE-IT).
3. If LDL-C target still not met on ezetimibe alone: Add bempedoic acid 180 mg, or switch to Nexlizet (bempedoic acid + ezetimibe fixed-dose) for adherence convenience.
4. If LDL-C target still >70 mg/dL with combined oral therapy: Escalate to a PCSK9 inhibitor (evolocumab or alirocumab subcutaneous injection every 2-4 weeks; LDL-C reduction 50-60%).
5. Absolute ASCVD high-risk with LDL-C >190 mg/dL: Consider inclisiran (Leqvio) 284 mg subcutaneous twice yearly as an alternative injectable option.

Dosing, Administration, and Drug Interactions

The approved dose is 180 mg orally once daily with or without food. No dose adjustment is needed for mild to moderate renal impairment (eGFR 30-60 mL/min/1.73m²). Bempedoic acid has not been adequately studied in severe renal impairment (eGFR <30) or end-stage renal disease, and use in those populations requires clinical judgment [2].

Hepatic impairment: mild impairment (Child-Pugh A) does not require dose adjustment. The drug is not recommended in moderate or severe hepatic impairment [2].

Key drug interaction table from the FDA prescribing information:

• Simvastatin: cap at 20 mg/day to avoid increased myopathy risk
• Pravastatin: cap at 40 mg/day
• Cyclosporine: avoid concurrent use (large increase in bempedoic acid exposure via OATP inhibition)
• Atorvastatin, rosuvastatin: no dose adjustment required; monitor for muscle symptoms

The drug carries a Pregnancy Category X-equivalent warning. Cholesterol synthesis is required for fetal development, and ACL inhibition may harm the fetus. Women of childbearing potential must use reliable contraception and have a negative pregnancy test before initiation [2].

Safety Profile: What to Monitor

The most clinically meaningful adverse effect from CLEAR Outcomes was hyperuricemia. Bempedoic acid raised serum uric acid by a mean of 1.2 mg/dL from baseline, and gout occurred in 3.1% of the bempedoic acid group versus 2.1% placebo (P<0.001) [3]. Patients with a history of gout or baseline uric acid above 6 mg/dL (women) or 7 mg/dL (men) warrant close monitoring and a frank conversation about this risk before starting.

Cholelithiasis (gallstones) appeared at slightly higher frequency: 2.2% vs. 1.2% in CLEAR Outcomes [3]. The biological explanation may involve altered hepatic lipid flux.

Tendon rupture was reported rarely in earlier pooled Phase 2/3 data and is listed as a warning in the prescribing information. Patients who perform high-impact exercise or who have prior tendinopathy should be informed [2].

Liver enzyme elevations (AST or ALT above three times the upper limit of normal) occurred in 0.3% of bempedoic acid patients in CLEAR Outcomes, no different from placebo [3]. Routine transaminase monitoring is not required by labeling but may be prudent at baseline and at 12 weeks in patients on hepatotoxic background medications.

The ACC/AHA 2022 Guideline on Nonstatin Therapies states: "In patients with statin-associated muscle symptoms, bempedoic acid is a reasonable addition to maximally tolerated statin therapy or as monotherapy to reduce LDL-C" (Class IIa, Level B-R) [5].

Who Is a Good Candidate for Nexletol?

The strongest candidates are adults with documented ASCVD or heterozygous familial hypercholesterolemia (HeFH) who have discontinued two or more statins due to muscle side effects. CLEAR Outcomes enrolled exactly this population, so the 13% MACE reduction applies directly to them [3].

Secondary candidates include patients who are partially controlled on a low-to-moderate intensity statin and who decline PCSK9 inhibitor injections. In that setting, bempedoic acid provides incremental LDL lowering through a completely different mechanism.

Poor candidates: patients who tolerate high-intensity statin therapy well and have reached their LDL-C goal, patients with active gout or recurrent nephrolithiasis, and patients on cyclosporine or other potent OATP inhibitors.

The 2022 National Lipid Association Expert Panel notes that bempedoic acid "lowers LDL-C by an additional 18% when used as add-on to statin therapy and by 24% as monotherapy, with consistent reductions in hsCRP of approximately 22-25%" [12]. The hsCRP reduction suggests a possible anti-inflammatory mechanism beyond LDL lowering, though the CLEAR Outcomes design does not permit isolation of that signal.

Cost, Access, and Practical Prescribing Notes

Nexletol (bempedoic acid 180 mg tablets, 30-count) carries a list price of approximately $395-430/month. Nexlizet (bempedoic acid 180 mg / ezetimibe 10 mg, 30-count) runs approximately $440-465/month. No generic formulation had received FDA approval as of January 2025 [2].

Esperion's patient assistance program (EsperAssist) offers copay cards that reduce out-of-pocket costs to as low as $10/month for commercially insured patients. Medicare Part D coverage varies by plan; many require prior authorization documenting statin intolerance with supporting clinical notes.

Insurance documentation requirements typically include: documented muscle symptoms or CK elevation on at least one prior statin, a trial of at least two different statins at any dose, and a cardiovascular risk assessment placing the patient in high- or very-high-risk category per ACC/AHA pooled cohort equation.

When writing a prior authorization, cite CLEAR Outcomes (NEJM 2023) and the ACC/AHA Class IIa, Level B-R recommendation. Specific language matching the insurer's non-statin therapy criteria significantly improves first-pass approval rates.